Login
Companies $AEON
$0.15 +$0.01 (7.46%) After hours
AEON Biopharma, Inc. logo

AEON Biopharma, Inc.

aeonbiopharma.com

What Do They Do?

Develops a botulinum toxin biosimilar candidate for therapeutic use by healthcare providers treating patients.

Who Are Their Customers?

Healthcare providers purchase botulinum toxin products that they administer to patients; prescribing decisions reflect clinical considerations, reimbursement, practice economics, workflow and familiarity with existing products.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▲ Turned profitable
vs −$4.5M in Q3 FY2025
  • Sep 30, 2026 FDA feedback supports planned ABP-450 study and potential use of earlier studies AEON plans an investigational application in the fourth quarter of 2026 and to start the study in the first quarter of 2027.

From acquisition vehicle to drug developer The older report describes a company formed to pursue a business combination, focused on medical technology. The latest report describes a biopharmaceutical company developing a therapeutic botulinum toxin biosimilar.

Who Do They Compete With?

Competes with AbbVie, Dysport, Xeomin, and Evolus

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support